You are here: Home » 2022 » August » Archives for 8th

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TGTX

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TG Therapeutics, Inc. (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, both dates inclusive (the "Class Period"), of the important September 16, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TG Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TG Therapeutics class action, go to https://rosenlegal.com/submit–form/?case_id=7662 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) clinical trials revealed significant concerns related to the benefit–risk ratio and overall survival data of Ublituximab (an investigational glycoengineered monoclonal antibody for the treatment of B–cell non–hodgkin lymphoma, chronic lymphocytic leukemia ("CLL"), and relapsing forms of multiple sclerosis) and Umbralisib (or UKONIQ, an oral inhibitor of PI3K–delta and CK1–epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma); (2) accordingly, it was unlikely that TG Therapeutics would be able to obtain U.S. Food and Drug Administration ("FDA") approval of the marginal zone lymphoma ("MZL") and follicular lymphoma ("FL") (the "Umbralisib MZL/FL NDA"), the rolling submission of a Biologics License Application ("BLA") to the FDA for Ublituximab in combination with Umbralisib (together, "U2"), as a treatment for patients with CLL (the "U2 BLA"), the supplemental New Drug Application ("sNDA") for Umbralisib to add an indication for CLL and small lymphocytic lymphoma ("SLL") in combination with Ublituximab (the "U2 sNDA"), or the Ublituximab as a treatment for patients with relapsing forms of multiple sclerosis ("RMS") (the "Ublituximab RMS BLA") in their current forms; (3) as a result, TG Therapeutics had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (4) therefore, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TG Therapeutics class action, go to https://rosenlegal.com/submit–form/?case_id=7662 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages MINISO Group Holding Limited Investors to Inquire About Securities Class Action Investigation – MNSO

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MINISO Group Holding Limited (NYSE: MNSO) resulting from allegations that MINISO may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased MINISO securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=7814 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On July 26, 2022, during trading hours, market analyst Blue Orca Capital published a report regarding MINISO Group Holding Limited which alleges several issues with the Company including that "MINISO Lies about its Core Business Model" because "MINISO claims that 99% of its stores in China, its key market, are operated by franchisees independent from the Company. " Through our investigation, " we found over 620 supposedly independent franchises, which, according to Chinese corporate records, are registered under the names of MINISO executives or individuals closely connected to the Company's chairman[,]" and "MINISO Admitted in Chinese Media that 40% of Stores Directly Owned." The report further alleges that "IPO Proceeds Siphoned by Chairman through Crooked Headquarters Deal." Finally, the report alleges that MINISO is a "Retailer In Decline: Shrinking Revenues, Falling Franchise Fees and Store Closures[,]" due in part to "Franchise Fees Dropped by 63%, Indicating Lagging Interest."

On this news, MINISO American Depositary Share (ADS) price fell $1.08 per ADS, or 14%, to close at $6.13 per ADS on July 26, 2021, on unusually heavy trading volume. On July 27, 2022, MINISO's ADSs closed at $5.66 per ADS, representing more than a 70% decline from the $20.00 IPO price.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

DREAM enrollment complete, 12–month clinical data expected in fall of 2023

Mont–Saint–Guibert, Belgium "" August 8, 2022, 10:05pm CET / 4:05pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022.

Second Quarter 2022 Financial and Operating Highlights

  • Completed enrollment in DREAM U.S. pivotal trial; expect 12–month clinical data in the fall of 2023 and regulatory approval in the first half of 2024
  • Generated revenue of 935,000 from the commercialization of Genio in Europe, primarily in Germany, which represents growth of more than five times the amount achieved in the second quarter of 2021
  • Activated 11 new implanting sites in Germany during the second quarter, bringing the total to 26 as of June 30, 2022; expecting to have at least 35 active implanting sites by the end of 2022
  • Received FDA approval of IDE submission to commence the ACCCESS study to treat complete concentric collapse (CCC) patients in the U.S., with first patient implant expected in the fourth quarter of 2022
  • Received FDA approval of the next generation Genio 2.1 system for use in the DREAM study and CE mark for use in commercial patients in Europe; this improves patient comfort and compliance with a new smartphone application and upgraded external activation chip, which leverages Nyxoah's scalable platform to continuously enhance patient comfort and therapy efficacy without requiring a new implant
  • Partnered with Acurable to distribute the AcuPebble SA100 wearable home sleep test to OSA patients in Germany; launch is expected in the fourth quarter of 2022
  • Included in the newly formed Euronext Tech Leaders Index, which is composed of 100+ innovative and high–growth technology companies with greater than 1 trillion in aggregate market capitalization

"We made significant progress on all of our key strategic priorities this quarter, including activating 11 new commercial sites in Germany, completing enrollment in our DREAM trial, and receiving approval for our ACCCESS IDE," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "From a commercial standpoint, our second quarter performance showing 42% quarter–over–quarter growth strengthens our confidence that we will achieve market leadership status in Germany by the end of 2022."

"As the only commercially available hypoglossal nerve stimulation (HGNS) therapy approved for the treatment of CCC patients, we are encouraged by the first strong results from patients who are six months post–implantation. These results, combined with no longer having to perform a drug–induced sleep endoscopy (DISE) procedure prior to implant, are driving physicians to recommend Genio for their CCC and non–CCC patients," continued Mr. Taelman.

Mr. Taelman concluded, "In the meantime, we have already begun investing in our U.S. market access organization. As for our ACCCESS study, we expect to implant the first patients before year end."

Second Quarter and First Half 2022 Results

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION "" INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022 (in thousands)

For the three months ended June 30 For the six months ended June 30
2022 2021 2022 2021
Revenue 935 170 1 595 355
Cost of goods sold ( 334) ( 63) ( 623) ( 115)
Gross profit 601 107 972 240
Research and Development Expense ( 3 470) ( 2 398) ( 7 065) ( 5 492)
Selling, General and Administrative Expense ( 4 536) ( 3 913) ( 8 729) ( 6 279)
Other income/(expense) 14 ( 101) 150 ( 97)
Operating loss for the period ( 7 391) ( 6 305) ( 14 672) ( 11 628)
Financial income 4 670 39 6 246 43
Financial expense ( 2 162) ( 574) ( 2 950) ( 899)
Loss for the period before taxes ( 4 883) ( 6 840) ( 11 376) ( 12 484)
Income taxes ( 107) ( 99) ( 315) ( 124)
Loss for the period ( 4 990) ( 6 939) ( 11 691) ( 12 608)
Loss attributable to equity holders ( 4 990) ( 6 939) ( 11 691) ( 12 608)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences ( 12) 262 ( 114) 192
Total comprehensive loss for the year, net of tax ( 5 002) ( 6 677) ( 11 805) ( 12 416)
Loss attributable to equity holders ( 5 002) ( 6 677) ( 11 805) ( 12 416)
Basic Loss Per Share (in EUR) ( 0,193) ( 0,314) ( 0,453) ( 0,570)
Diluted Loss Per Share (in EUR) ( 0,193) ( 0,314) ( 0,453) ( 0,570)

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION "" INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT JUNE 30, 2022 (in thousands)

As at
June 30
2022		 December 31 2021
ASSETS
Non–current assets
Property, plant and equipment 2 111 2 020
Intangible assets 32 570 25 322
Right of use assets 3 410 3 218
Deferred tax asset 1 429 46
Other long–term receivables 180 164
39 700 30 770
Current assets
Inventory 506 346
Trade receivables 957 226
Other receivables 1 548 2 286
Other current assets 852 1 693
Financial assets 47 717 '
Cash and cash equivalents 75 602 135 509
127 182 140 060
Total assets 166 882 170 830
EQUITY AND LIABILITIES
Capital and reserves
Capital 4 438 4 427
Share premium 228 158 228 033
Share based payment reserve 4 411 3 127
Other comprehensive income 88 202
Retained loss (98 850) (87 167)
Total equity attributable to shareholders 138 245 148 622
LIABILITIES
Non–current liabilities
Financial debt 8 089 7 802
Lease liability 2 859 2 737
Pension liability 80 80
Provisions 44 12
Deferred tax liability ' 5
11 072 10 636
Current liabilities
Financial debt 661 554
Lease liability 672 582
Trade payables 4 301 3 995
Current tax liability 4 391 2 808
Other payables 7 540 3 633
17 565 11 572
Total liabilities 28 637 22 208
Total equity and liabilities 166 882 170 830

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS AS AT JUNE 30, 2022 (in thousands)

For the six months ended June 30
2022 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year (11 376) (12 484)
Adjustments for
Finance income (6 246) (43)
Finance expenses 2 950 899
Depreciation and impairment of property, plant and equipment and right–of–use assets 536 377
Amortization of intangible assets 402 428
Share–based payment transaction expense 1 292 '
Increase/(Decrease) in provisions 32 '
Other non–cash items 37 11
Cash generated before changes in working capital (12 373) (10 812)
Changes in working capital
Decrease/(Increase) in inventory (160) (27)
(Increase)/Decrease in trade and other receivables 1 011 (3 463)
Increase/(Decrease) in trade and other payables 2 053 6 061
Cash generated from changes in operations (9 469) (8 241)
Income tax paid ( 254) ( 111)
Net cash used in operating activities (9 723) (8 352)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment (302) (795)
Capitalization of intangible assets (7 650) (3 726)
(Increase)/Decrease in financial assets – current (44 032) '
Net cash used in investing activities (51 984) (4 521)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities (317) (236)
Repayment of other loan (42) (42)
Interests paid (134) (258)
Repayment of recoverable cash advance ' (105)
Proceeds from issuance of shares, net of transaction costs 136 362
Other financial costs (8) (10)
Net cash generated from financing activities (365) (289)
Movement in cash and cash equivalents (62 072) (13 162)
Effect of exchange rates on cash and cash equivalents 2 165 33
Cash and cash equivalents at January 1 135 509 92 300
Cash and cash equivalents at June 30 75 602 79 171

Revenue

Revenue was 935,000 for the second quarter ending June 30, 2022, compared to 170,000 for the second quarter ending June 30, 2021. Revenue for the first half of 2022 was 1.6 million, compared to 355,000 for the first half of 2021. The increase in revenue was attributable to the Company's commercialization of the Genio system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was 334,000 for the three months ending June 30, 2022, representing a gross profit of 601,000, or gross margin of 64.3%. This compares to total cost of goods sold of 63,000 in the second quarter of 2021, for a gross profit of 107,000, or gross margin of 62.9%.

For the six months ending June 30, 2022, total cost of goods sold was 623,000, representing a gross profit of 972,000, or gross margin of 60.9%. This compares to total cost of goods sold of 115,000 in the first half of 2021, for a gross profit of 240,000, or gross margin of 67.6%.

Research and Development Expenses

Research and Development expenses were 3.5 million for the three months ending June 30, 2022, versus 2.4 million for the prior year period, reflecting the Company's investments in the development of next generation versions of the Genio system as well as ongoing clinical studies, most notably DREAM in the U.S.

For the six months ending June 30, 2022, Research and Development expenses were 7.1 million, versus 5.5 million for the first half of 2021.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses rose to 4.5 million for the second quarter of 2022, up from 3.9 million in the second quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

For the six months ending June 30, 2022, Selling, General and Administrative expenses were 8.7 million, up from 6.3 million in the first half of 2021 due to increased commercial efforts in Germany and investments in Nyxoah's corporate infrastructure.

Operating Loss

Total operating loss for the second quarter and first half of 2022 was 7.4 million and 14.7 million, respectively, versus 6.3 million and 11.6 million in the second quarter and first half of 2021, respectively. This was driven by the acceleration in the Company's R&D spending, as well as ongoing commercial and clinical activities. Nyxoah realized a net loss of 5.0 million and 11.8 million for the second quarter and first half of 2022, respectively, compared to a net loss of 6.7 million and 12.4 million for the second quarter and first half of 2021, respectively.

Cash Position

As of June 30, 2022, cash and financial assets totaled 123.3 million, compared to 135.5 million on December 31, 2021. Total cash burn was approximately 2.0 million per month during the first half of 2022. Nyxoah expects monthly cash burn to increase in the second half of 2022 to account for the commencement of the ACCCESS IDE trial in the U.S., and the current cash position provides ample liquidity to get to U.S. commercialization in 2024.

First Half 2022 Report

Nyxoah's financial report for the first half of 2022, including details of the audited consolidated results, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30 p.m. CET / 4:30 p.m. ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial–in number: https://register.vevent.com/register/BIfc3a52c9352e4e42958e9d816245b3b9

A question–and–answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com

+1 917 749 14

Attachment


ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Yext, Inc. Investors to Secure Counsel Before Important August 16 Deadline in Securities Class Action – YEXT

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Yext, Inc. (NYSE: YEXT) between March 4, 2021 and March 8, 2022, both dates inclusive (the "Class Period"), of the important August 16, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Yext securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Yext class action, go to https://rosenlegal.com/submit–form/?case_id=7115 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 16, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Yext's revenue and earnings were significantly deteriorating because of, among other things, poor sales execution and performance, as well as COVID–19 related disruptions; (2) accordingly, Yext was unlikely to meet consensus estimates for its full year ("FY") fiscal 2022 financial results and fiscal 2023 outlook; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Yext class action, go to https://rosenlegal.com/submit–form/?case_id=7115 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Wells Fargo & Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – WFC

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Wells Fargo & Company (NYSE: WFC) between February 24, 2021 and June 9, 2022, both dates inclusive (the "Class Period"), of the important August 29, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Wells Fargo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Wells Fargo class action, go to https://rosenlegal.com/submit–form/?case_id=7261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Wells Fargo had misrepresented its commitment to diversity in the Company's workplace; (2) Wells Fargo conducted fake job interviews in order to meet its Diverse Search Requirement; (3) the foregoing conduct subjected Wells Fargo to an increased risk of regulatory and/or governmental scrutiny and enforcement action, including criminal charges; (4) all of the foregoing, once revealed, was likely to negatively impact Wells Fargo's reputation; and (5) as a result, Wells Fargo's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Wells Fargo class action, go to https://rosenlegal.com/submit–form/?case_id=7261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


ROSEN, GLOBAL INVESTOR COUNSEL, Encourages 17 Education & Technology Group Inc. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Commenced by the Firm – YQ

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of 17 Education & Technology Group Inc. (NASDAQ: YQ) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with 17EdTech's December 2020 initial public offering (the "IPO"), of the important September 19, 2022 lead plaintiff deadline, in the securities class action commenced by the Firm.

SO WHAT: If you purchased 17EdTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the 17EdTech class action, go to https://rosenlegal.com/submit–form/?case_id=7395 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) Defendant 17EdTech's K–12 Academic AST Services would end less than a year after the IPO; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the 17EdTech class action, go to https://rosenlegal.com/submit–form/?case_id=7395 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


Graduate Management Admission Council Appoints Joy Jones as Incoming CEO

RESTON, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) — The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today announced the appointment of Joy Jones as the organization's CEO–Elect. Jones currently serves as GMAC's chief product officer and general manager of assessments, a role she has held since July 2017. The announcement came after current CEO Sangeet Chowfla announced his intention to step down from the position earlier this year, and an extensive search executed by a global executive recruiting firm. The GMAC board of directors unanimously voted to elect Jones, who will become GMAC's fourth CEO as of October 1, 2022.

"With more than a hundred interested candidates from around the world, the Board conducted extensive interviews and thorough evaluations over the past months and was thrilled to find the best person to lead the organization from within," said Jon Erickson, chairman of the GMAC board of directors and former president of education and career services at ACT. "Besides her proven success with growing GMAC products and services and deep understanding of the graduate management education industry we represent, we were especially impressed by Ms. Jones's vision, intellect, composure, and ability to relate to people."

Jones joined GMAC five years ago with the responsibility for holistically managing the Council's assessments and preparation portfolio, which includes the Graduate Management Admission Test (GMAT) exam""the most widely used assessment by business schools worldwide and relied on by more than 7,500 business school programs, the NMAT by GMAC exam, Executive Assessment, and associated assessment preparation materials. She was instrumental in navigating through challenging times during the COVID–19 pandemic with a rapid launch of the online delivery of all GMAC assessment solutions. Earlier this year, under her stewardship, GMAC debuted Business Fundamentals Powered by Kaplan, a new GMAC product line of "micro" courses in statistics, accounting, and finance to help prepare business school aspirants and admitted students for success in their graduate programs.

"It is a great honor for me to be chosen to lead a long–standing and highly regarded organization like GMAC, with an outstanding 70–year history of connecting talent with opportunity through higher education," said Jones. "As the organization enters into a new chapter in an ever–evolving global business environment, focused on innovation and growth as well as diversity and inclusion, I look forward to continuing to work alongside my dedicated colleagues at GMAC and in the business school community to advance graduate management education and ensure that talented people have the opportunity to improve the world we live in."

Throughout her career, Jones has been a transformational leader in a variety of roles spanning strategy, product, sales, business development, and operations, with expertise in leveraging new technologies to create innovative solutions for global markets. Prior to joining GMAC, Jones had a 13–year tenure at the Associated Press (AP) which culminated as their Vice President of Global Products, overseeing all product portfolio and distribution platform management across the company's multimedia content licensing, advertising, and content service businesses. Prior to AP, Jones worked at Cap Gemini Ernst & Young, where she was an executive with the Strategic Advisory Services and Telecom Media Networks consulting practices. She earned her MBA at Stanford University and holds a bachelor's degree in mathematics and applied sciences from the University of California, Los Angeles (UCLA), where she graduated with honors.

Jones will succeed Sangeet Chowfla, who has chosen to step down for a new phase of his life after nearly a decade at the helm of GMAC. Chowfla joined GMAC in 2013 and served as President and CEO since 2014. During his tenure, Chowfla drove an extraordinary period of transformation and diversification for GMAC, including establishing regional offices in China, India, and the U.K., and oversaw three acquisitions of complementary products and services designed to help foster connections with candidates and schools, namely NMAT by GMAC, BusinessBecause, and The MBA Tour. He also helped redefine the GMAC brand in renewing focus on serving member schools and uniting the industry to solve common problems and created additional value for schools through expanding our research programs, conferences, and events. Chowfla will continue as an advisor through the end of the year to be available for a smooth and orderly transition.

"Sangeet Chowfla joined the organization during a period of disruption in the industry that only intensified with the advent of the pandemic and global geopolitical challenges," said Erickson. "We are grateful for his service and the extraordinary growth and evolution that has enabled us to build long–term strategies and position our association for the future to continue serving schools and candidates."

"It has been an honor and privilege to lead this great organization in a time of change," said Chowfla. "GMAC's mission, its people, and the connections that it fosters are truly unique. I look back with some satisfaction that we have built a stronger and more resilient GMAC that is leaner, more diversified in its service offerings, and more global in its outlook. Joy and I have worked closely over the years, and I leave secure in knowing that she has the vision and capability to lead the organization and take it forward."

About GMAC

The Graduate Management Admission Council (GMAC) is a mission–driven association of leading graduate business schools worldwide. Founded in 1953, GMAC provides world–class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test (GMAT) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC's websites, including mba.com, to learn about MBA and business master's programs, connect with schools around the world, prepare and register for exams and get advice on successfully applying to MBA and business master's programs. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202–390–4180 (mobile)
thsu@gmac.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b997ea7e–87f4–4d87–979a–e5ecde0379fc


Post-War Italian Supercars join Stellar Offering of European Grand Touring Cars as Final Additions to the 90 Car Lineup for the inaugural Broad Arrow Monterey Jet Center Auction

Monterey, CA, Aug. 08, 2022 (GLOBE NEWSWIRE) —

  • Monterey Jet Center Auction includes the 28–car offering of the "Fleischman Collection", Watch the full–length video of Senior Car Specialist David Swig and owner William "Bill" Fleischman as they discuss some of the highlights of the collection, largely offered without reserve
  • The exquisite 1939 Mercedes–Benz 540K Spezial Roadster is highlighted in a newly released full–length video featuring independent Automotive Historian Jonathan Sierakowski who discusses the numerous merits and unique aspects of the Spezial Roadster
  • Watch the full–length video of Sir Sean Connery's personal 1964 Aston Martin DB5 including an interview with longtime friend Sir Jackie Stewart along with Ben Collins, aka "The Stig" who shares his driving experience of the car

Broad Arrow Auctions is delighted to announce the final consignments for the upcoming Monterey Jet Center Auction this 18 August in Monterey, California. The inaugural auction for the company will feature an impressive selection of motor cars ranging from pre–war and post–war American and European Classics to a wide selection of modern collectibles and supercars. The complete digital catalogue can be viewed here

The Broad Arrow auction will be held on Thursday, 18 August at 4:00 pm PDT, with a public preview opening Wednesday, 17 August at 9:00 am until 3:00 pm PDT and a private preview starting at 5:00 pm for the guests of the Hagerty Motorlux event, tickets for which can be purchased directly at www.motorlux.com. Public preview on Thursday, 18 August, will open at 9:00 am PDT, with the auction open to registered bidders and their guests only beginning at 4:00 pm PDT.

Kenneth Ahn, President of Broad Arrow Group, said, "We are excited to announce the full lineup of cars and memorabilia for Broad Arrow Group's inaugural auction. We have been working diligently over the past several months to assemble a world–class offering that we believe will excite car collectors and enthusiasts around the world. We are deeply appreciative of many clients who have entrusted us to offer their cars at our first–ever auction. I also want to recognize the tremendous efforts from our car specialists, team members, and our partners at Hagerty. We look forward to welcoming collectors, enthusiasts, and industry participants to our inaugural Monterey Jet Center Auction this August."

Final additions to the roster include the 1995 Ferrari F50, with an estimate of $4,400,000 – $5,000,000. An exceptional example and one of only 349 originally produced, the three–owner car presented here just received its annual service at Ferrari of Houston and is fully documented by Ferrari historian Marcel Massini. Ferrari Classiche Certified in 2017, the USA–spec F50 is accompanied by all tool kits, hardtop cases, and appropriate handbooks.

Another show–stopping highlight is the 1971 Mercedes–Benz 600 Pullman (LWB) Six–Door Landaulet, with an estimate of $2,000,000 – $2,500,000, and one of just 26 six–door 600 Pullman landaulets built between 1963 and 1981, constructed ostensibly without regard or concern for cost. A fully numbers–matching example, the 600 Pullman has benefitted from a spectacular restoration without compromise by Kienle Automobiltechnik between 2016 and 2020. First owned by the Democratic Republic of Congo, it was factory ordered with a hydraulically actuated glass partition, intercom system, television, and tape recorder.Arguably one of the very finest examples extant, the availability of these regal and rare Landaulets is indeed noteworthy.

Following the theme of the world's most elegant and rare post–war British and European cars, the 1954 Bentley R–Type Continental Sports Saloon by H.J. Mulliner, is an equally prized motor car. Estimated to achieve $2,200,000 – $2,600,000 at auction, the example presented here is the 1954 New York Auto Show Car which is one of just 41 left–hand drive standard shift cars. Notably, it was first owned by William Brewster, associated with famed Rolls–Royce coach builder Brewster & Co. Today, it is simply resplendent following a complete restoration by marque specialists, Vantage Motorworks in Miami, Florida.

Another grand touring highlight of the auction includes the 1957 Bentley Continental S1 Fastback Sports Saloon by H.J. Mulliner (Estimate: $800,000 – $1,000,000). And for something completely different, a 2013 Mercedes–Benz G500 Cabriolet Final Edition (Estimate: $500,000 – $600,000) also joins as yet another rare and interesting car included within the auction. Additional Ferrari highlights also include an outstanding example of the iconic 1990 Ferrari F40, with an estimate of $1,950,000 – $2,150,000 as well as a virtually brand new and well–specified 2011 Ferrari 599 GTO, with an estimate of $750,000 – $950,000.

Another fitting entry for the auction is the 1991 Jaguar XJR–15 (estimate: $1,600,000 – $1,900,000). This exceptionally well–prepared example is fitted with an upgraded air conditioning system, shows less than 700 miles from new, and benefits from over $20,000 spent perfecting the car since July 2021. Lastly, one of the ultimate in Italian sports cars, the 1969 Lamborghini Miura P400 S (Estimate: $1,600,000 – $1,900,000) joins the offering. One of only a select few finished in Argento Indianapolis Metallizzato; the matching numbers example has benefitted from years of routine care and maintenance throughout its life.

The Broad Arrow Auction will take place on Thursday, 18 August, at the Monterey Jet Center alongside the Motorlux event that builds on the legacy of McCall's Motorworks Revival under Hagerty's stewardship. The auction will feature 91 exceptional motor cars and includes previously announced highlights led by Sir Sean Connery's personal 1964 Aston Martin DB5 being offered on behalf of the Connery family. Additional highlights include a stunning 1957 Ferrari 250 GT LWB "Tour de France" and seven low–mileage modern supercars from The Halo Collection. Further details on all consignments can be found at www.broadarrowauctions.com.

About Broad Arrow Group

Broad Arrow Group and its subsidiaries "" Broad Arrow Auctions, Broad Arrow Capital, and Collectors Garage "" represent the collective vision of its founders, team members, and partners "" to be the best advisor, marketplace, and financier for car collectors, with integrity, trust, and innovation. Broad Arrow Group was founded in 2021 to develop and operate a portfolio of businesses and brands that address the various segments of the collector car market and to transform the collector car industry. In January 2022, Hagerty (NYSE: HGTY) made a strategic investment and became a joint venture partner of Broad Arrow Group. Learn more at www.broadarrowgroup.com.

Attachments


Winners Announced in the Seventh Annual Stevie® Awards for Great Employers

FAIRFAX, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) — Winners in the 2022 (seventh annual) Stevie Awards for Great Employers, an international competition, were announced today. The awards recognize the world's best employers and the human resources professionals, teams, achievements, and HR–related products and suppliers who help to create and drive great places to work.

Among the organizations with the most Stevie–winning nominations are IBM, worldwide (27 Gold, Silver, and Bronze wins), Tata Consultancy Services, worldwide (23), Enerjisa Enerji, Turkey (21), Bank of America, USA (18), Cathay United Bank, Taiwan (10), Globe Telecom, Inc., Philippines (10), MGROS, Turkey (10), Abu Dhabi Customs, United Arab Emirates (8), DHL Global Forwarding, Germany (8), Sabanci Holding, Turkey (8), GA (stanbul Grand Airport), Turkey (7), Megaphone, Australia (7), and NEQSOL HOLDING, Azerbaijan (7).

Visit www.StevieAwards.com/HR for a full list of winners by category.

Next week two Grand ("best of show") Stevie Award winners will be announced. One will go to the nomination that received the highest average score from the judges. The other, for Organization of the Year, will go to the entrant with the most award points earned in the competition.

The Grand, Gold, Silver, and Bronze Stevie Award winners will be celebrated during an awards banquet on September 17 at Caesars Palace in Las Vegas. Tickets for the event are now on sale.

More than 950 nominations from organizations in 26 nations were evaluated in this year's competition. Winners were determined by the average scores of more than 100 professionals worldwide, acting as judges. Winners in the Employer of the Year categories, sponsored by HiBob, were determined by a unique blending of the average scores of the professional judges and more than 80,000 votes by the general public.

The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Categories include:

  • Employer of the Year
  • HR Achievements
  • HR Individual Awards
  • HR Team Categories
  • Solution Provider Awards
  • COVID–19 Response
  • More than 50 New Product & Service Categories
  • Thought Leadership

The awards are presented by the Stevie Awards, which organizes eight of the world's leading business awards programs including the prestigious International Business Awards and American Business Awards .

About the Stevie Awards
Stevie Awards are conferred in eight programs: the Asia–Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards , The International Business Awards , the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

About HiBob
HiBob is a modern HR platform designed for modern business. HiBob's intuitive and data–driven platform, "Bob', was built for the way people work today: globally, remotely, and collaboratively. Since its launch in late 2015, HiBob has achieved consecutive triple–digit year–over–year revenue growth and become the HR platform of choice for more than 2,500 modern, midsize, and multinational companies who understand that a powerful, agile HR tech suite is mission critical and a key driver of organizational success. Dynamic companies across the globe such as Cazoo, Gong, Hopin, Monzo, Happy Socks, Fiverr, and VaynerMedia rely upon Bob to help HR and managers connect, engage, develop and retain top talent. For more information about HiBob, visit www.hibob.com.

Contact:
Nina Moore
Nina@StevieAwards.com
+1 (703) 547–8389

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3be33011–bf0f–469a–ac50–1f037f0aa9c3


J.M. Huber Corporation Signs Agreement to Acquire the Biolchim Group From NB Renaissance, Chequers Capital and Management Team

ATLANTA, Aug. 08, 2022 (GLOBE NEWSWIRE) — J.M. Huber Corporation (Huber)""a global, family–owned specialty engineered materials manufacturing company""announced today that it has signed a binding agreement to acquire full control of the Biolchim Group from NB Renaissance, Chequers Capital and the Biolchim Group management team. The Biolchim Group, managed and headed by Galileo Quattro SARL, has its main operating base in Italy and is a leading producer and distributor of a full range of specialty plant nutrition and biostimulants. Closing of the sale, anticipated to occur by the end of 2022, is subject to customary closing conditions including the foreign direct investment approval in Italy.

All the companies in the Biolchim Group""including Biolchim S.p.A, Cifo, Ilsa S.p.A, Matcsa Kft, and West Coast Marine–Bio Processing Corp.""are within the scope of the purchase. The Biolchim Group operates eight production plants globally and its products""biostimulants, trace elements, and water soluble, liquid and foliar fertilizers""are present in over 70 countries worldwide. The Biolchim Group has a rich 50–year history of serving the agricultural industry.

Upon close of the sale, the Biolchim Group will become part of Huber Engineered Materials (HEM), a company within the Huber portfolio of businesses. The Biolchim Group will be a key part of the strategic foundation of the Huber AgroSolutions (HAS) business unit of HEM that currently includes Miller Chemical & Fertilizer (Miller).

Leonardo Valenti, CEO of the Biolchim Group since 2008 and a pioneer in the plant nutrition industry, will remain committed to lead the Biolchim Group through the next phase of growth and the integration, leveraging the synergy potential of the strategic combination of both entities.

Huber AgroSolutions' vision is to become a leading formulator of sustainable, high–performing agricultural products globally. The acquisition of the Biolchim Group, which has achieved impressive growth due to its broad offering of biostimulant and specialty nutritional products, significantly advances this vision by bringing an innovative and entrepreneurial workforce and culture to HAS. Together the companies share a culture that is deeply committed to plant nutrition and the success of its many customers around the globe.

The complementary sales footprint of both companies will enable expanded customer and product access into key agricultural regions globally. In addition to remaining committed to serve the Biolchim Group's existing customer base, this also ideally positions HAS to advance the sales of the Biolchim Group's products through its strong relationships with US–based growers and its complementary distribution network in Latin America and select countries in Europe, the Middle East and Africa. The Biolchim Group's sales channels are ideally suited to advance the sales of various Miller products via its strength in Europe and its global subsidiary network.

"I am excited and energized about this opportunity to combine two successful businesses, Miller and the Biolchim Group," says David Riley, Senior Vice President and General Manager of Huber AgroSolutions. "I am also thankful to Mr. Valenti for his leadership and support as we transition the Biolchim Group and Miller to the next phase of growth."

Leonardo Valenti, CEO of the Biolchim Group, says, "The strategic combination of the Biolchim Group and Huber AgroSolutions will be transformative since the companies have complementary commercial and product offerings, as well as industry–leading technologies and research capacities. We are both eager to collaborate, share knowledge and build on each other's capabilities. The agreement will open up new growth ambitions and will position us as a leading player in specialty nutrition globally. I am excited about the promising future for the company, and I am grateful to NB Renaissance and Chequers Capital for the continuous support received over the past several years through the implementation of the Biolchim Group's value creation plan and the key strategic decisions."

"Miller and the Biolchim Group create a powerful combination of brands, people and specialty products that will bring tremendous value to our respective customers globally," says Dan Krawczyk, President of HEM. "We're extremely excited to welcome the Biolchim Group's employees to Huber given the similarities in our cultures, values and goals. Together we will work to shape the future of the organization and build a leading global business in the agriculture industry."

Gretchen McClain, President and CEO of J.M. Huber Corporation, adds, "This combination furthers our commitment to provide innovative products and solutions to the global agriculture industry. Enabling food security for people around the world supports Huber's overall sustainability commitment and strategy."

Huber is being advised on the purchase by Rabobank and Jefferies, and Jones Day is acting as legal counsel to Huber on the transaction.

About J.M. Huber Corporation
J.M. Huber Corporation, headquartered in Atlanta, Georgia (US), operates a diverse portfolio of companies: CP Kelco, Huber Engineered Materials, Huber Engineered Woods and Huber Resources Corp. With locations around the world, our businesses create products used in a broad range of applications including personal care, food and beverage, agricultural nutrients and adjuvants, building materials, flame retardants and smoke suppressants, as well as sustainable forestry services. Founded in 1883, Huber is one of the largest family–owned companies based in the US. For more information, visit www.huber.com.

About Huber Engineered Materials
Huber Engineered Materials (HEM), headquartered in Atlanta, Georgia (US) is focused on engineered specialty chemical and minerals that enhance the performance, appeal and processing of a broad range of products used in industrial, agricultural and consumer applications. HEM's AgroSolutions strategic business unit also has a portfolio of high value agricultural nutrients and adjuvants that it delivers to customers in the agriculture industry through a global network of distributors. For more information, visit www.hubermaterials.com.

MEDIA CONTACT:
Lea Volpe
Director, Corporate Communications
J.M. Huber Corporation
678.247.7128 phone
lea.volpe@huber.com